Vimarsana
Biggest News Aggregation in the World

Expanded Phase News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Expanded Phase. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Expanded Phase Today - Breaking & Trending Today

AGTC Clinical Investigators Provide Encore Presentation of Data from the Company's Ongoing XLRP ... - Vimarsana News

AGTC Clinical Investigators Provide Encore Presentation of Data from the Company's Ongoing XLRP ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. AGTC Clinical Investigators Provide Encore Presentation of Data from the Company’s Ongoing XLRP ... Applied Genetic Technologies CorporationMay 3, 2021 GMT -Company remains on track to present additional 12-month data from the XLRP and achromatopsia clinical trials in the second quarter of 2021- ALACHUA, Fla. and CAMBRIDGE, Mass., May 03, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated vi...

Source: apnews.com
Children's Health Defense Calls for More Study of Pfizer COVID Vaccine for Seniors and Blacks in Advance of Emergency Use Authorization (EUA) in These Populations - Vimarsana News

Children's Health Defense Calls for More Study of Pfizer COVID Vaccine for Seniors and Blacks in Advance of Emergency Use Authorization (EUA) in These Populations

Children's Health Defense Calls for More Study of Pfizer COVID Vaccine for Seniors and Blacks in Advance of Emergency Use Authorization (EUA) in These Populations News provided by Share this article Share this article WASHINGTON, Dec. 10, 2020 /PRNewswire/ -- Children's Health Defense (CHD) is raising significant concerns based on the briefing released for the FDA's Vaccines and Related Biological Products Advisory Committee meeting scheduled Thursday, December 10 th, to review the Pfizer coronavirus vaccine BNT162b2. Less than 2.1% of the safety study cohort had been followed for over three...